NTT East and NTT Life Science will utilize the results and interview information of NTT East Izu Hospital’s complete medical checkup and the information of NTT Life Science’s genetic testing service “Genovision Dock” to recommend appropriate optional tests according to individual risks. Demonstration project of service “Smart medical examination” has started.
The target diseases are cerebral infarction, colon cancer, and pancreatic cancer.
We will analyze the effects of “Smart medical examination” based on evaluations from participants through questionnaires and evaluations as a medical institution through hearings, and conduct verifications for social implementation.
NTT East and NTT Life Science are aiming to start commercial services after the next fiscal year.